Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6016036 | 1.00 | HDAC6 (0.41) | HDAC6CTSKHDAC1HDAC2HDAC3 | |
| SCHEMBL12743336 | 0.89 | HDAC6 (0.41) | HDAC6CTSKHDAC1HDAC2HDAC3 | |
| SCHEMBL3139219 | 0.89 | HDAC6 (0.41) | HDAC6CTSKHDAC1HDAC2HDAC3 | |
| SCHEMBL883432 | 0.89 | HDAC6 (0.41) | HDAC6CTSKHDAC1HDAC2HDAC3 | |
| SCHEMBL4736565 | 0.83 | HDAC6 (0.36) | HDAC6CTSKHDAC1HDAC2ELANE | |
| SCHEMBL1598833 | 0.82 | ALDH1A1 (0.41) | — | |
| SCHEMBL10595745 | 0.82 | ALDH1A1 (0.41) | — | |
| SCHEMBL789539 | 0.82 | HDAC6 (0.37) | HDAC6CTSKHDAC1HDAC2ELANE | |
| SCHEMBL3698014 | 0.82 | HDAC6 (0.37) | HDAC6CTSKHDAC1HDAC2ELANE | |
| SCHEMBL16594410 | 0.82 | HDAC6 (0.37) | HDAC6CTSKHDAC1HDAC2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646638-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | Enanta Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| WO-2004108745-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004108746-A2 | 11-12 BICYCLIC ERYTHROMYCIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
| US-20040254126-A1 | 11-12 Bicyclic erythromycin derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| US-6790835-B1 | Bicyclic macrolide derivatives | ENANTA PHARMACEUTICALS, INC. | 2004-09-14 | — | — | US | disclosed |
| US-6774115-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-08-10 | — | — | US | disclosed |
| US-6765016-B1 | 11,12-CYCLIZED ERYTHROMYCIN DERIVATIVE BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-07-20 | — | — | US | disclosed |
| US-6716820-B1 | BACTERICIDES | ENANTA PHARMACEUTICALS, INC. | 2004-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254126-A1 | 11-12 Bicyclic erythromycin derivatives | ABCB11, CYP51A1, CYP2C19 | HDAC6 257/4885CTSK 2551/4885HDAC1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.